- Complement Pharma to receive up to a total of € 14 million in milestone-dependent payments through Phase 1b development
- Alexion has option to acquire Complement Pharma during the term of the agreement
Strategic Initiative
Slingshot members are tracking this corporate initiative:
Alexion Pharmaceuticals (ALXN) has agreed to co-develop CP010, a C6 complement inhibitor for the potential treatment of neurodegenerative disorders, with Complement Pharma
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ALXN |
|
|
||||
Additional Information
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date: Jun 11, 2018 Projected Implementation: Q2, 2018 Relevance Tracked Until: Q4, 2018
Related Projects
-
Don’t see a project related to the strategic initiative you care about?
Related Keywords
Cp010, C6 Complement Inhibitor, Neurodegenerative Disorder
